Mitochondrial Metabolism and Oxidative Stress in Function of the Physical Exercise and Nutritional Counseling in T2DM
MITOX
2 other identifiers
interventional
146
1 country
1
Brief Summary
The goal of this ancillary study is to learn about the effects of different aerobic modalities (moderate-intensity continuous training (MICT) and high-intensity interval training (HIIT)) and diet on mitochondrial properties and oxidative stress in patients with prediabetes or type 2 diabetes (T2D), and overweight or obesity. It will also learn about the different effects of these interventions in men and women. The main questions it aims to answer are:
- What is the isolated and combined effect of these exercise modalities and diet? Is there a superior approach for mitochondrial metabolism and oxidative stress in patients with T2D?
- Is there a sex-specific best combination choice for these different interventions?
- Is there any relation between exercise and diet-induced changes in mitochondrial properties and oxidative stress and other health-related outcomes such as body composition or insulin sensitivity? To answer these questions, researchers designed a two-factor study. One factor was exercise, which had three levels (MICT, HIIT, and the inactive (INACT) condition). The second factor was diet, with two levels (Diet (D) and no diet (ND)). Hence, participants were randomly allocated into 6 groups: INACT-ND, INACT-D, MICT-ND, MICT-D, HIIT-ND, and HIIT-D. Participants did:
- Underwent a 12-week intervention within the condition of his/her group
- Visit the research group facilities three times per week if in an exercise group or once every two weeks if in a diet group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable diabetes-mellitus-type-2
Started Mar 2022
Longer than P75 for not_applicable diabetes-mellitus-type-2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 10, 2022
CompletedFirst Submitted
Initial submission to the registry
September 26, 2025
CompletedFirst Posted
Study publicly available on registry
November 26, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedSeptember 15, 2026
September 1, 2026
3.8 years
September 26, 2025
September 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Muscle biopsy samples: mitochondrial respiratory capacity
Skin was locally anesthetized, followed by an incision of approximately 6-7mm on the dermal surface. Using sterilized Bergstrom needles, approximately 3-6 mg of skeletal muscle from the lateral vastus were extracted and placed in a BIOPS buffer for immediate analysis of mitochondrial respiration (MR) through high-resolution respirometry. Before, the fibers were mechanically separated in BIOPS buffer using sterilized needles and chemically permeabilized with a 50 μg/ml saponin solution. MR was measured in a specific buffer (Mir05) in duplicate in hyperoxygenated chambers (250-450 nmol/mL of oxygen) in an Oxygraph-2k at 37ºC (Oroboros, Innsbruck, Austria). A substrate-uncoupler titration protocol was employed by adding (final concentration): malate (2mM), pyruvate (5mM), glutamate (2mM), MgCl2 (3mM), and ADP (5mM), cytochrome C (10μM), succinate (10mM), and p-trifluoromethoxyphenylhydrazone. Oxygen flux was presented as mass-specific (pmol·s/mg wet weight) and normalized to CS activity.
Pre and post the 12-week intervention
Assessed changes in Oxidative Stress
The level of oxidative stress was assessed by the concentration of 8-OHdG as a biomarker of DNA oxidation. A competitive ELISA detection method was employed in serum samples. Briefly, the standard and the sample were added to a pre-coated microplate along with the biotinylated detection antibody. After washing, HRP-Streptavidin was added. Then, the TMB substrate was added, and the reaction was terminated with an acid solution. The color production was measured spectrophotometrically at a wavelength of 450nm. The optical density values of samples were compared with those of the standard curve to determine the 8-OHdG concentration (ng/ml).
Pre and post the 12-week intervention
Muscle biopsy sample: Citrate Synthase activity
2-5 mg of frozen muscle was homogenized in a 1:20 dilution of CelLytic™ MT Tissue Lysis (C3228, Sigma-Aldrich, Dorset, UK), with 1 % protease inhibitor cocktail (P8340, Sigma-Aldrich, Dorset, UK) at 4 °C. The lysate was centrifuged at 12,000 × g for 10 min at 4 °C to pellet debris, and the supernatant was stored at -80 °C. CS activity was quantified in duplicates using an assay kit following the manufacturer's instructions (CS0720: Sigma-Aldrich, Dorset, UK). Briefly, endogenous activity was recorded through color emission by DTNB, and total activity was calculated after the addition of oxalacetate. Protein concentration was determined in duplicates using a bicinchoninic acid assay kit (BCA1: Sigma-Aldrich, Dorset, UK), enabling normalization of CS activity values to total protein content (µmol/g/min). CS activity and protein concentration were measured in 96-well plates using a microplate reader at 412 nm and 562 nm, respectively (MQX200R2, Biotek instruments, Burlington, USA).
Pre and post the 12-week intervention
Secondary Outcomes (27)
Assessed changes in Glucose concentration
Pre and Post the 12-week intervention
Assessed changes in Insulin concentration
Pre and Post the 12-week intervention
Assessed changes in Insulin Resistance: HOMA-IR
Pre and Post 12-week intervention
Assessed changes in Tissue Oxygenation Index
Pre and post the 12-week intervention
Assessed changes in haemoglobin saturation delta
Pre and post the 12-week intervention
- +22 more secondary outcomes
Study Arms (6)
ND-INACT
NO INTERVENTIONParticipants who did not receive either nutritional intervention or exercise program. They were instructed to maintain their normal life habits regarding physical activity and diet.
Moderate-intensity continuous training (ND-MICT)
ACTIVE COMPARATORParticipants who did not receive nutritional intervention but were enrolled in a moderate-intensity continuous training exercise program.
High-intensity interval training (ND-HIIT)
ACTIVE COMPARATORParticipants who did not receive nutritional intervention but were enrolled in a high-intensity interval training exercise program.
Nutritional intervention (D-INACT)
ACTIVE COMPARATORParticipants who received nutritional intervention but not an exercise program.
Nutritional Intervention Moderate-Intensity continuous training (D-MICT)
EXPERIMENTALParticipants who received nutritional intervention and were enrolled in a moderate-intensity continuous training exercise program.
Nutritional Intervention High-intensity interval training (D-HIIT)
EXPERIMENTALParticipants who received nutritional intervention and were enrolled in a high-intensity interval training exercise program.
Interventions
The nutritional intervention was conducted through biweekly (± 3 days) in-person consultations with a nutritionist or dietitian. Firstly, the patient's diet was analyzed. Then, participants were guided to follow a mildly calorie-restricted diet (-250-500 kcal/day deficit), with the primary goal of achieving a 5 % reduction in body weight and reducing blood glucose levels. Meal plans were created using Nutrium® software , personalized to each participant's lifestyle and food preferences, and reviewed at each biweekly consultation. The dietary plan included at least 4 or 5 meals per day, ensuring a well-distributed intake of carbohydrates, a balanced distribution of macro- and micronutrients, and the inclusion of foods rich in prebiotics and probiotics. Moreover, some suggestions about the combination of foods and culinary techniques were provided. Only one session through the intervention was allowed to be attended telephonically.
Participants assigned to the HIIT completed 3 weekly sessions, with 1-2 days of rest between sessions, on a cycle ergometer for 12 weeks. The training load (TL) was determined from an incremental test until volitional exhaustion with one-minute work intervals (from 85% to 165% of maximal power output from a previously performed VO2max test \[Wmax\] and with 10% increments) separated by 1.5-minute rest periods (at 20% Wmax). The program consisted of a 3 minutes warm-up with the first 2 minutes at 20% and last minute at 40% of the TL, followed by 10 series of 1 min duration at 90% of TL, with 1 minute of rest between sets at 20% of TL and ending with 2 minutes of cool-down at 20% of TL (estimated total time of the session: 25 minutes). A 5% increase in workload was applied when, for two consecutive sessions, the first three intervals failed to exceed 85%, and at least five did not reach 90% of maximal HR. Participants were asked to maintain a cadence above 80RPM.
Participants assigned to the MICT completed 3 weekly sessions, with 1-2 days of rest between sessions, on a cycle ergometer for 12 weeks. MICT consisted of 50 minutes of continuous pedaling at an intensity approximately 10 % above the lactate threshold, with a cadence between 60-80 rpm. Training load (TL) was increased by 10% if these two conditions were met: 1) no increase of at least 2 beats of heart rate from minute 20 to minute 40 of the training session, and 2) lactate levels below 2 mmol/L in minute 48 of the session. The TL for the first session was determined by an adjustment test consisting of an incremental test with five consecutive 10-minute phases at a constant cadence (60-80 RPM) from 90% to 130% of the ventilatory threshold power, calculated from previously performed FatOx test data, with 10% increments in each step. TL was determined by the phase in which HR increased by ≥ 3 beats between phases and blood lactate levels increased by ≥ 1 mmol/L from the previous phase.
Eligibility Criteria
You may qualify if:
- Diagnosis of T2D or prediabetes (glycated hemoglobin ≥ 5.7%)
- No history of substance abuse (tobacco, alcohol, or other drugs).
- Body mass index ≥25 kg/m², maintaining habitual dietary patterns with stable body weight for at least 6 months
- Stable physical activity and medication regimen for at least 6 months
- Lack of habitual vigorous-intensity physical activity and the presence of sedentary behavior characterized by prolonged sitting time (screened using the International Physical Activity Questionnaire short form).
- Not insulin-dependent
- Absence of injury, disease, disability, or other known medical condition which could affect the ability to successfully participate in physical exercise tests
- Absence of tumors and cancer disease
- Absence of other pathologies that could affect the study outcomes.
- Not on a medication regimen that could affect the study outcomes.
- Being able to understand communication in Spanish or English.
- Not pregnant
You may not qualify if:
- Failure to attend more than 2 consecutive sessions or a total of 4 sessions of nutritional intervention.
- Failure to attend more than 4 consecutive or a total of 6 sessions of physical training.
- Serious injury
- Voluntary withdrawal
- Increased dose of diabetes medication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Science of Education Faculty
Puerto Real, Cádiz, 11510, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cristina Casals Vázquez, PhD
University of Cádiz
- PRINCIPAL INVESTIGATOR
Miguel Efrén Jiménez Romero, MD
Hospital de la Línea de la Concepción
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Due to the nature of the intervention, participants and intervention providers can not be blinded. However, outcome assessors and statisticians remained blinded to group allocation. Additionally, the randomization procedure was administered by an independent researcher.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2025
First Posted
November 26, 2025
Study Start
March 10, 2022
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
September 15, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share